Frequency and Predictors of Drug-Eluting Stent Use in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions A Report From the American College of Cardiology National Cardiovascular Data CathPCI Registry by Brilakis, Emmanouil S. et al.
F
U
P
A
N
E
S
B
C
D
a
O
d
B
i
M
S
G
v
R
o
w
h
4
P
C
r
s
2
F
T
N
F
s
s
S
D
h
h
C
a
P
E
2
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 1 0 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 0 . 0 7 . 0 0 9requency and Predictors of Drug-Eluting Stent
se in Saphenous Vein Bypass Graft
ercutaneous Coronary Interventions
Report From the American College of Cardiology
ational Cardiovascular Data CathPCI Registry
mmanouil S. Brilakis, MD, PHD,* Tracy Y. Wang, MD, MHS,‡ Sunil V. Rao, MD,‡
ubhash Banerjee, MD,* Steven Goldman, MD,§ Kendrick Shunk, MD, PHD,
iswajit Kar, MD,† David R. Holmes, JR, MD,¶ David Dai, MS,‡
hee T. Chin, MBCHB,‡ Tina M. Harding, RN, BSN,‡ Matthew T. Roe, MD, MHS‡
allas and Houston, Texas; Durham, North Carolina; Tucson, Arizona; San Francisco, California;
nd Rochester, Minnesota
bjectives We examined a large registry to determine the frequency and factors associated with
rug-eluting stents (DES) use in saphenous vein graft (SVG) in contemporary practice.
ackground Prospective trials comparing DES with bare-metal stents in SVG lesions have provided conﬂict-
ng conclusions regarding safety and efﬁcacy leading to potential variation in stent choice for these lesions.
ethods We analyzed the frequency and factors associated with DES use in patients undergoing
VG stenting from January 1, 2004, to March 31, 2009, in the National Cardiovascular Data Registry.
eneralized estimating equations logistic regression modeling was used to generate independent
ariables associated with DES use in SVGs.
esults During the study period, percutaneous coronary intervention (PCI) of a SVG represented 5.7%
f the total PCI volume (91,355 of 1,596,966). Of the 84,875 patients who received a SVG stent, a DES
as used in 64.5%. From 2005 to 2009, DES use in SVG PCI changed from 80% to 62%. Unfractionated
eparin was used in 46%, enoxaparin in 17%, bivalirudin in 42%, and a glycoprotein IIb/IIIa inhibitor in
0% of cases. On multivariable analysis, several parameters (including the period, multivessel PCI, prior
CI, no acute myocardial infarction, and no smoking) were associated with DES use.
onclusions Currently, DES are used in nearly two-thirds of SVG interventions. Several clinical pa-
ameters (such as the period of implantation and the complexity of coronary artery disease) are as-
ociated with the decision to implant a DES in these challenging lesions. (J Am Coll Cardiol Intv
010;3:1068–73) © 2010 by the American College of Cardiology Foundation
rom the *Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center at Dallas, Dallas,
exas; †Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; ‡Duke Clinical Research Institute, Durham,
orth Carolina; §Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona; University of California San
rancisco, San Francisco, California; and the ¶Mayo Clinic College of Medicine, Rochester, Minnesota. Dr. Brilakis has received
peaker honoraria from St. Jude Medical, consulting fees from Medicure, and research support from Abbott Vascular; furthermore, his
pouse is an employee of Medtronic. Dr. Wang has received research support from Bristol-Myers Squibb/Sanofi Partnership,
chering-Plough, The Medicines Company, Heartscape Technologies, Canyon Pharmaceuticals, and Eli Lilly/Daiichi Sankyo Alliance.
r. Rao has received research funding from Cordis Corporation, Momenta Pharmaceuticals, and Portola Pharmaceuticals; and speaker
onoraria from The Medicines Company, Sanofi-Aventis, Bristol-Myers Squibb, and AstraZeneca. Dr. Banerjee has received speaker
onoraria from St. Jude Medical, Medtronic, and Johnson & Johnson; and research support from Boston Scientific and The Medicines
ompany. Dr. Roe has received research funding from Eli Lilly, Bristol-Myers Squibb, Sanofi-Aventis, and Merck-Schering Plough;
nd consulting and honoraria from GlaxoSmithKline, Novartis, Eli Lilly, Bristol-Myers Squibb, Sanofi-Aventis, Merck-Schering
lough, and AstraZeneca. All other authors report that they have no relationships to disclose. Morton J. Kern, MD, served as Guest
ditor for this paper. This paper was presented at the American College of Cardiology 59th Annual Scientific Session, March 14–16,
010, Atlanta, Georgia.anuscript received March 22, 2010; revised manuscript received June 25, 2010, accepted July 12, 2010.
D
b
i
s
a
r
i
c
c
(
e
f
d
N
t
p
M
P
d
N
p
P
C
a
h
a
p
s
N
i
t
c
o
e
u
M
d
S
l
p
S
m
a
a
w
b
t
c
t
i
m
i
d
b
d
h
h
c
S
p
w
f
t
fi
d
c
c
e
i
s
I
s
a
s
i
c
s
w
p
t
w
w
C
D
l
r
a
R
P
b
T
h
s
c
b
c
p
3
a
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 0 , 2 0 1 0 Brilakis et al.
O C T O B E R 2 0 1 0 : 1 0 6 8 – 7 3 DES Use in SVGs in NCDR Registry
1069rug-eluting stents (DES) have been shown to be superior to
are-metal stents (BMS) in all coronary lesion subsets exam-
ned, except 1: saphenous vein grafts (SVG) (1). Although 7
tudies with follow-up angiography showed less late lumen loss
nd lower restenosis rates with DES (1), the 2 prospective
andomized-controlled trials that compared DES with BMS
n SVGs provided conflicting results, with 1 study showing
linical benefit with DES (2,3) and the other showing in-
reased late mortality with DES (4,5). We used the NCDR
National Cardiovascular Data Registry) CathPCI registry to
valuate the contemporary use of DES in SVGs and to identify
actors most commonly associated with DES versus BMS use
uring SVG percutaneous coronary intervention (PCI). The
CDR allows assessment of contemporary DES usage pat-
erns in a real-world patient population rather than the selected
atients included in randomized clinical trials.
ethods
atient population. The NCDR CathPCI registry receives
ata from 800 participating hospitals in the U.S. The
CDR CathPCI registry is a national quality improvement
rogram focused on diagnostic cardiac catheterization and
CI and is a partnership between the American College of
ardiology and the Society for Cardiovascular Angiography
nd Interventions. The CathPCI registry includes in-
ospital data on patients undergoing cardiac catheterization
nd PCI procedures. This is a standard dataset with
re-specified definitions, uniform data entry and transmis-
ion requirements, and data quality checks. Participation in
CDR is voluntary and the registry only collects data on
n-hospital events. Moreover, there is no core lab adjudica-
ion of the angiographic parameters. Details on the data
ollection process and the variable definitions have previ-
usly been published (6). For the purpose of this study, we
xamined the index PCI for CathPCI registry patients
ndergoing SVG stenting from January 1, 2004, through
arch 31, 2009. Of the 1,596,966 patients undergoing PCI
uring this period, 91,355 (5.7%) underwent PCI of an
VG lesion. Of those, 84,875 received either a BMS or at
east 1 DES in an SVG and were included in the final study
opulation.
tatistical analysis. Continuous variables were presented as
ean SD. Categorical variables were reported as percent-
ges. The baseline characteristics, PCI procedural findings,
nd in-hospital outcomes were compared between patients
ho received a BMS or DES in SVG lesions. Comparisons
etween groups were performed using Pearson chi-square
ests for all categorical variables and Wilcoxon tests for all
ontinuous variables.
Multivariable logistic regression analyses were performed
o determine variables associated with DES versus BMS use
n SVGs. The following parameters were entered into theodel: age, sex, race, body mass index, prior myocardial anfarction, prior valvular surgery, cardiac transplantation,
iabetes, creatinine clearance, history of renal failure, cere-
rovascular disease, peripheral arterial disease, chronic lung
isease, hypertension, current smoking, dyslipidemia, family
istory of coronary artery disease, prior PCI, congestive
eart failure, New York Heart Association heart failure
lass, cardiogenic shock, and symptoms on admission.
imilarly, multivariable logistic regression analyses were
erformed to determine whether the use of BMS or DES
as independently associated with in-hospital mortality
ollowing SVG PCI. The following parameters were en-
ered in the model: age, body mass index, glomerular
ltration rate, New York Heart Association functional class,
ialysis, ST-segment elevation, cardiogenic shock, prior
ongestive heart failure, prior valve surgery, prior cardiovas-
ular disease, peripheral arterial disease, chronic lung dis-
ase, prior percutaneous coronary intervention, insertion of
ntra-aortic balloon pump before PCI, ejection fraction,
ubacute thrombosis, TIMI (Thrombolysis In Myocardial
nfarction) flow pre-stenting, diabetes, lesion class, lesion
egment, age, and sex (7). Because patients within a hospital
re more likely to be treated in a
imilar way, generalized estimat-
ng equations models with ex-
hangeable working correlation
tructure were used to adjust for
ithin hospital correlation.
All tests were 2-sided, and
 0.05 was considered statis-
ically significant. All analyses
ere performed using SAS soft-
are (version 9.1, SAS Institute,
ary, North Carolina) by the
uke Clinical Research Institute (Durham, North Caro-
ina). The authors had full access to the data and take
esponsibility for its integrity. All authors have read and
greed to the manuscript as written.
esults
atient and procedural characteristics. The patients’
aseline and treatment characteristics are summarized in
ables 1 and 2. Most patients were men, and they had a
igh prevalence of diabetes, hyperlipidemia, and hyperten-
ion. A high prevalence of both cardiovascular (prior myo-
ardial infarction, prior PCI, congestive heart failure, cere-
rovascular and peripheral arterial disease) and noncardiac
omorbities (such as obesity, renal failure, and chronic
ulmonary disease) was observed. The body mass index was
0 or more in 39.5% of the patients.
Approximately two-thirds of the patients presented with
n acute coronary syndrome. Most patients (53.7%) received
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
OR  odds ratio
PCI  percutaneous
coronary intervention
SVG  saphenous vein graft
TIMI  Thrombolysis In
Myocardial Infarctionnticoagulation with unfractionated heparin. Bivalirudin
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1070as used in 41.5% of patients. A glycoprotein IIb/IIIa
nhibitor was also utilized in approximately 40% of patients.
Drug-eluting stents were used in 54,715 of 84,875
atients (64.5%). Drug-eluting stent utilization was 68%
n 2004, 80% in 2005, 75% in 2006, 53% in 2007, 55% in
008, and 62% in 2009. This paralleled the use of DES in
ative coronary artery lesions, which was 87% in 2004, 90%
n 2005, 87% in 2006, 69% in 2007, 73% in 2008, and 79%
n 2009.
Most target lesions (63.4%) were located in the SVG
ody, with 20.3% of the lesion being located in the SVG
ortic anastomosis and 16.2% in the SVG distal anastomo-
is. Almost one-half of target SVGs had a TIMI flow grade
Table 1. Comparison of Baseline Patient Characteristics in the
CathPCI Registry Patients Undergoing SVG Stenting Classified
According to the Type of Stent They Received
Variable
All Patients
(n  84,875)
DES
(n  54,715)
BMS
(n  30,160) p Value
Demographics
Age, yrs 69 10 69 10 70 11 0.001
Men 77.4% 76.9% 78.2% 0.001
White race 88.6% 88.3% 89.0% 0.001
Comorbidities
Hypertension 86.9% 86.8% 87.2% 0.08
Hyperlipidemia 87.6% 87.9% 87.1% 0.001
Diabetes mellitus 0.01
Non–insulin-dependent 27.7% 28.0% 27.1%
Insulin-dependent 16.1% 16.1% 16.1%
Smoking 0.001
Current 17.2% 15.9% 19.6%
Former 45.5% 45.9% 44.7%
Prior MI 48.4% 48.1% 49.1% 0.001
Prior PCI 44.4% 47.4% 38.8% 0.001
Cerebrovascular disease 19.8% 19.3% 20.7% 0.001
Peripheral arterial disease 23.3% 22.6% 24.5% 0.001
History of renal failure 9.2% 8.7% 10.3% 0.001
Chronic lung disease 17.9% 17.0% 19.7% 0.001
Warfarin use 5.7% 5.2% 6.6% 0.001
Body mass index, kg/m2 29.4 5.7 29.4 5.6 29.4 5.8 0.77
Presentation
Symptoms 0.001
No angina 10.9% 10.6% 11.4%
Atypical chest pain 5.7% 5.8% 5.5%
Stable angina 15.9% 17.0% 13.8%
ACS: unstable angina 40.7% 42.6% 37.2%
ACS: NSTEMI 20.3% 18.9% 22.9%
ACS: STEMI 6.5% 5.1% 9.2%
Congestive heart failure 14.0% 12.9% 16.1% 0.001
Cardiogenic shock 1.6% 1.2% 2.3% 0.001
ACS  acute coronary syndrome; BMS  bare-metal stent(s); DES  drug-eluting stent(s);
MI  myocardial infarction; NSTEMI  non–ST-segment elevation acute myocardial infarction;
PCI  percutaneous coronary intervention; STEMI  ST-segment elevation acute myocardial
infarction; SVG saphenous vein graft.3 before stenting, but TIMI flow grade 3 was restored inearly all SVGs after stenting. A large amount of contrast
nd long fluoroscopy time was needed. An embolic protec-
ion device was used in 23% of patients (26% of patients
eceiving BMS and 21% of patients receiving DES). In-
ospital mortality was higher among patients receiving
MS versus DES (2.02% vs. 1.01%, odds ratio [OR]: 2.05,
 0.001). After adjusting for multiple predictors of
n-hospital mortality (7), use of BMS in SVG lesions
emained independently associated with in-hospital mortal-
ty (OR: 1.35, p  0.001).
actors associated with DES use. Compared with patients
eceiving a BMS, those receiving a DES were more likely to
ndergo treatment of in-stent restenotic lesions, to undergo
ultivessel PCI and less likely to receive warfarin, to have a
IMI flow grade 3 at baseline, to undergo treatment of a
Table 2. Comparison of Lesion Characteristics, Treatments, and Immediate
Procedural Outcomes in the CathPCI Registry Patients Undergoing SVG
Stenting Classified According to the Type of Stent They Received
Variable
All Patients
(n  84,875)
DES
(n  54,715)
BMS
(n  30,160) p Value
Lesion characteristics
Restenotic lesion 8.2% 10.0% 5.0% 0.001
Lesion location 0.001
Aortic anastomosis 20.3% 20.5% 19.8%
SVG body 63.4% 61.5% 66.8%
Distal anastomosis 16.2% 17.9% 13.2%
Lesion length, mm 19.1 12.3 19.2 12.6 18.8 11.9 0.001
Treatment
Unfractionated heparin 53.7% 52.9% 55.0% 0.001
Enoxaparin 17.3% 17.3% 17.2% 0.73
Bivalirudin 41.5% 41.7% 41.2% 0.19
Glycoprotein IIb/IIIa
inhibitor
39.7% 39.4% 40.4% 0.003
Multivessel PCI 11.6% 14.1% 7.1% 0.001
Number of stents
implanted
0.001
1 62.0% 59.0% 67.5%
2 or more 38.0% 41.0% 32.5%
Pre-procedure TIMI ﬂow
grade
0.001
3 52.0% 53.2% 49.8%
2 24.8% 24.8% 24.8%
1 13.2% 13.2% 13.2%
0 9.2% 8.0% 11.5%
Post-procedure TIMI ﬂow
grade
0.001
3 96.5% 97.2% 95.2%
2 2.1% 1.6% 2.9%
1 0.5% 0.4% 0.8%
0 0.7% 0.6% 0.9%
Intra-aortic balloon pump 2.1% 1.5% 3.0% 0.001
Fluoroscopy time, min 18.3 12.6 18.4 12.6 18.1 12.5 0.001
Contrast use, ml 219 103 223 105 213 100 0.001TIMI Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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1071istal anastomotic lesion, or to present with cardiogenic
hock (Tables 1 and 2). On multivariable analysis, several
ariables were associated with DES use (Table 3). The
trongest determinant of DES use was the period when
VG stenting was performed, followed by multivessel PCI
nd prior PCI (Table 3).
iscussion
ata from the CathPCI registry demonstrated that DES are
urrently being utilized in the majority of SVG PCI procedures
n the U.S. and identified several variables associated with stent
election for these challenging lesions. From 2005 to 2009,
ES use for SVG PCI decreased from 80% to 62%.
Whether DES provide an incremental benefit over BMS
or the treatment of SVG lesions remains controversial
Table 3. Variables Associated With DES Use in SVG
Variable
Odds
Ratio
Lowe
Confiden
Year-quarter 0.91 0
Multivessel PCI 2.03 1
Prior PCI 1.40 1
Acute myocardial infarction 0.78 0
Smoking 0.78 0
SVG lesion location
Body vs. distal anastomotic 0.67 0
Aortic vs. distal anastomotic 0.76 0
Warfarin use 0.76 0
Age (per 5-year increase) 0.96 0
Baseline TIMI ﬂow grade
3 vs. 0 1.28 1
2 vs. 0 1.24 1
1 vs. 0 1.24 1
Cardiogenic shock 0.70 0
Congestive heart failure 0.87 0
History of renal failure 0.87 0
Female sex 1.11 1
Body mass index (per 5-U increase) 0.97 0
Chronic lung disease 0.91 0
Hypercholesterolemia 1.09 1
Peripheral vascular disease 0.94 0
Diabetes
Non–insulin-dependent 1.06 1
Insulin-dependent 1.06 1
White race 0.92 0
Prior MI 0.95 0
NYHA functional class
4 vs. 1 1.02 0
3 vs. 1 1.08 1
2 vs. 1 1.08 1
Prior cardiovascular disease 0.96 0
Other factors included in the multivariable model that were not sign
hypertension, and prior cardiac transplantation.NYHA New York Heart Association functional class; other abbreviations a1,8). Although DES consistently and significantly reduce
ate loss and angiographic restenosis in SVGs (1,8), their
linical safety and efficacy in this setting is still debated, in
arge part due to the results of the RRISC (Reduction of
estenosis In Saphenous Vein Grafts With Cypher
irolimus-Eluting Stent) trial (4,5). In the RRISC trial,
ompared with patients undergoing SVG PCI with BMS,
hose who received a DES (sirolimus-eluting) had lower
ngiographic restenosis and target vessel revascularization at
months, but higher mortality and similar rates of target
essel revascularization at 32 months (5,9). Although the
igher mortality in the DES arm was in part due to
oncardiac deaths and although the BMS group had an
nexpected 0% late mortality, the RRISC trial raised
oncerns about a higher rate of late stent thrombosis in
s
erval
Upper 95%
Confidence Interval Chi-Square p Value
0.92 706 0.0001
2.15 642 0.0001
1.44 479 0.0001
0.81 168 0.0001
0.81 152 0.0001
80 0.0001
0.70
0.81
0.81 74 0.0001
0.97 69 0.0001
55 0.0001
1.36
1.32
1.32
0.78 45 0.0001
0.91 39 0.0001
0.91 29 0.0001
1.15 28 0.0001
0.98 27 0.0001
0.95 21 0.0001
1.14 15 0.001
0.97 13 0.0001
15 0.0006
1.09
1.11
0.97 11 0.001
0.98 10 0.002
15 0.002
1.08
1.13
1.14
1.0 4 0.04
were family history of coronary artery disease, creatinine clearance,Lesion
r 95%
ce Int
.91
.92
.36
.75
.75
.64
.72
.71
.95
.21
.16
.16
.63
.83
.82
.07
.95
.88
.04
.91
.02
.02
.87
.93
.96
.03
.03
.93
ificants in Tables 1 and 2.
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1072ES-treated SVGs. In contrast, the only other prospective
andomized-controlled trial of DES in SVG, the SOS
Stenting of Saphenous Vein Grafts) multicenter trial,
howed significant angiographic and clinical benefit with
aclitaxel-eluting stent use in SVGs compared to BMS
uring 18 months of follow-up, without increased mortality
n the DES group (2). Moreover, stent failure after SVG
tenting often presented as an acute coronary syndrome and
ith complete SVG occlusion (3). Due to the small number
f patients included in the RRISC (n  75) and SOS (n 
0) trials, the debate on the optimum stent choice in SVGs
s likely to continue until results from 3 large ongoing or
lanned studies become available (1,8).
Our findings that DES are used in two-thirds of SVG
tenting procedures in the CathPCI registry suggest that
ost interventionalists consider DES to be beneficial in this
etting, even without definitive clinical trial proof of their
uperiority. Similarly, in the STENT (Strategic Transcath-
ter Evaluation of New Therapies) registry (10), SVG PCI
omprised 6.6% of all PCIs and DES were used in 70% of
VG lesions. Yet, the STENT registry (10) enrolled pa-
ients during an earlier period (2003 to 2006) than the
resent study (2004 to 2009) did, and, moreover, our study
xamined a much larger patient population with national
epresentation.
Several variables were associated with DES use in SVGs
n our study (Table 3). The period during which stenting
as performed was the strongest predictor of DES utiliza-
ion. Since the introduction of DES in the U.S. in 2003,
here was a rapid early adoption. In late 2005 and early
006, approximately 90% of all stents implanted in the U.S.
ere DES (11), yet DES use decreased after concerns for
ate stent thrombosis appeared in late 2006 (12). DES
tilization subsequently increased again after several studies
howed that although DES may have slightly higher risk for
ery late (1 year post-implantation) stent thrombosis
approximately 0.6% per year (13)), they also significantly
educe target vessel revascularization without increasing the
ncidence of death or myocardial infarction (14).
Currently, interventionalists are more likely to utilize
ES in multivessel PCI and for in-stent restenosis (15).
lso, BMS were preferred for acute myocardial infarction
atients, although recent data suggest that DES may be
uperior to BMS in this high-risk subgroup (16). Bare-
etal stents were also preferred for SVGs with TIMI flow
rade 0 at baseline and in sicker patients, such as those
resenting with congestive heart failure or cardiogenic
hock and those who needed intra-aortic balloon pump
nsertion, possibly because of concerns about the long-term
rognosis of such patients and the ability to tolerate long-
erm dual antiplatelet therapy. A high early mortality could
egate a potential benefit from DES use.
As has been previously reported (17), embolic protectionevice use was low (23% overall), although embolic protec-ion devices have a class I indication in the American Heart
ssociation and American College of Cardiology guidelines
18). Several factors may explain this low utilization, such as
he SVG lesion location, the absence of an adequate device
anding zone, increased cost and prolongation of the pro-
edure, and operator preference (19). In contrast, glyco-
rotein IIb/IIIa inhibitors were utilized in approximately
0% of procedures, although most currently available data
uggest that they are not beneficial in SVGs (20,21).
tudy limitations. Our study has limitations. Participation
n the CathPCI registry is voluntary; therefore, the results
ay not be representative of the entire U.S. SVG stenting
opulation, yet the number of participating sites is large and
he participating sites are committed to improving the
uality of clinical care. In the CathPCI registry, there is no
ore laboratory assessment of the patients’ angiograms.
lso, the CathPCI registry only collects data on the
n-hospital care of patients, and, as such, differences in
ong-term outcomes of patients receiving DES versus BMS
ould not be assessed. The rationale behind stent selection
n SVG PCI is not captured in CathPCI; therefore, unmea-
ured unknown variables (such as local stent availability,
eimbursement, patient compliance with dual antiplatelet
herapy, lack of health insurance, patient frailty, and other
onrecorded comorbidities) could be responsible for some
f the variability in DES use in SVG PCI. Some of the
ariables that were found to have a statistically significant
ssociation may not have a direct clinical association with
ES use in SVGs.
onclusions
ES are currently being used in nearly two-thirds of SVG
nterventions in spite of limited safety and efficacy data.
everal clinical parameters (such as the period of implanta-
ion and the complexity of coronary artery disease) are
ssociated with the decision to implant DES in these
hallenging-to-treat lesions. The impact of these findings
n the short- and long-term outcomes of patients under-
oing SVG PCI will require further study.
eprint requests and correspondence: Dr. Emmanouil S.
rilakis, VA North Texas Health Care System, The University of
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